Salivary Alterations in Rats with Experimental Chronic Kidney Disease by Romero, Ana Carolina et al.
RESEARCH ARTICLE
Salivary Alterations in Rats with Experimental
Chronic Kidney Disease
Ana Carolina Romero1, Cassia Toledo Bergamaschi2, Douglas Nesadal de Souza1,
Fernando Neves Nogueira1*
1 Departamento de Biomateriais e Biologia Oral, Faculdade de Odontologia, Universidade de São Paulo,
São Paulo, Brasil, 2 Departamento de Fisiologia, Escola Paulista de Medicina – UNIFESP, São Paulo, Brasil
* fnn@usp.br
Abstract
Objective
This study aimed to analyze changes in saliva composition and salivary secretion process
of rats with chronic kidney disease induced by 5/6 nephrectomy to set the foundation for sal-
ivary studies related to CKD.
Methods
CKD was induced in Wistar rats via 5/6 nephrectomy. Blood and saliva samples were col-
lected from Control, Sham and CKD groups at 8 and 12 weeks after the surgery. Salivation
was stimulated via intraperitoneal injections of pilocarpine (1.0 mg/Kg body weight) or iso-
proterenol (5.0 mg/Kg body weight). Saliva was collected and immediately stored at -80°C
until analysis. The salivary flow rate, total protein, amylase and peroxidase activities, and
urea concentrations were measured. The blood urea nitrogen (BUN) and serum creatinine
concentrations were also evaluated.
Results
Increases in BUN and serum creatinine concentrations were observed in the CKD groups.
Amylase activity was significantly reduced in response to both stimuli in the CKD groups at
8 weeks and increased in the CKD groups at 12 weeks in response to isoproterenol stimu-
lus. The peroxidase activities of the CKD groups were significantly reduced in response to
isoproterenol stimulation and were increased at 12 weeks in response to pilocarpine stimu-
lation. Salivary urea was significantly increased in the CKD groups at 8 weeks in response
to the isoproterenol stimuli and at 12 weeks in response to both salivary agonists.
Conclusions
The pattern of alterations observed in this experimental model is similar to those observed
in patients and clearly demonstrates the viability of 5/6 nephrectomy as an experimental
model in future studies to understand the alterations in salivary compositions and in salivary
glands that are elicited by CKD.
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Introduction
Chronic kidney disease (CKD) is a major problem in public health worldwide [1, 2]. CKD is a
progressive disorder marked by a loss of kidney function over time. The early stages of CKD
are characterized by kidney damage and are generally asymptomatic. As the kidney disease
worsens, kidney function begins to deteriorate, leading to end-stage kidney disease, which
requires kidney transplantation or hemodialysis [3].
Main oral manifestations of patients with chronic renal failure include odor of urea, dry
mouth, taste alterations, pain in the tongue and mucosa, gingivitis, periodontitis and a high
prevalence of dental calculus [4–7].
Saliva is an essential fluid in the oral cavity, being its chemical composition closely associ-
ated to major functions contributing to the maintenance of oral health. Studies of salivary alter-
ations in patients undergoing hemodialysis have reported decreases in stimulated and
unstimulated salivary flow [8, 9], increases in the pH and buffering capacity [8], increases in
protein secretion [9, 10], decreases in peroxidase enzymatic activity [9, 11], increases in the
amylase concentration [12] and changes in the secretion of electrolytes associated with the
increased secretions of phosphate, potassium, zinc, magnesium and urea [12–14]. Studies of
the accessory salivary glands of CKD patients have reported decreases in the function of these
glands, as determined by scintigraphy [15]; DNA damage, as observed with comet assays [16];
and atrophy and fibrosis observed via histological analyses [17].
Several experimental models of CKD have been used in studies with rats. Surgical renal
mass ablation, antibody induced-nephritis and renal artery branch ligation are the most com-
monly used methods [18]. The 5/6 nephrectomy procedure consists of the ligation of two
branches of the left renal artery and total right nephrectomy and results in the progressive
decline of renal function. This method has been used in several studies to evaluate the systemic
effects of CDK, such as cardiovascular alterations, proteinuria, changes in the liver function
and Ca and P metabolism, and anemia [19–21]. Despite this wealth of studies, salivary alter-
ations occurring in this experimental model of CKD in rats have not yet been analyzed.
This study aimed to determine the most significant changes in saliva composition and sali-
vary secretion process that typify rats with chronic kidney disease induced by 5/6 nephrectomy,
to establish the fundamentals for salivary studies related to CKD.
Materials and Methods
Animals
All animals were handled in accordance with the guidelines of Ethical Principles of Animal
Experimentation adopted by COBEA. The protocol of this study was approved by the Ethical
Committee for Animal Research of the Institute of Biomedical Sciences of the University of São
Paulo.
Eight-week old male Wistar rats were group-housed in individual cages in climate-con-
trolled conditions (22°C, 45–65% humidity, 12-h artificial light/dark cycle, noise level<55 dB)
with free access to standard rodent food (Purina, Brazil) and water. The animals were divided
into two main groups according to the experimental periods of 8 and 12 weeks. For each time
period, the groups were divided into the following 3 subgroups: Control, Sham, and Chronic
Kidney Disease (CKD). These subgroups were further divided into 2 groups according to
whether they received an isoproterenol or pilocarpine salivary stimulus. The final numbers of
animals in each group ranged from 8 to 10.
To induce CKD, a single phased 5/6 nephrectomy surgery was performed. The animals
were anesthetized with ketamine (100 mg/kg/bw) and xylazine (10 mg/kg/bw), ventral position
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placed on a surgical table, shaved and disinfected with 70% ethanol. The effects of anesthesia
were verified and complemented during the procedures. A ventral midline incision was made
to expose the left kidney hilum. The left renal artery was carefully dissected, and two of the
three branches were ligated with silk 6.0 lines, supported by a surgical microscope (Zeiss). The
right renal hilum was ligated in order to perform total nephrectomy on the right kidney [19,
21, 22].
The results of the CKD groups were compared with those of the control (normal) and sham
animals (i.e., animal submitted to the same surgical procedure without artery ligation and
nephrectomy). The experimental periods of 8 and 12 weeks were recorded from the day of sur-
gery and separation of the control animals.
Sample collection
Blood and saliva samples were collected from all of the subgroups in both the 8- and 12-week
experimental period groups.
Under the effect of anesthesia (ketamine and xylazine), salivation was stimulated by an
intraperitoneal injection of pilocarpine (1.0 mg/Kg body weight) or isoproterenol (5.0 mg/Kg
body weight), both of which were dissolved in distilled water, and the saliva that was produced
was dripped in plastic tubes and maintained on ice during all the saliva collection period (40
minutes) [23]. The salivary flow was determined, and the samples were centrifuged at 1,540 x g
at 4°C for 5 minutes. The supernatants were stored at -80°C for later analyses. Blood samples
were collected from the heart, stored in tubes containing EDTA (15%), centrifuged at 1,540 x g
for 10 minutes, and the sera refrigerated until analyses.
Analysis
Protein concentration (mg of protein/mL of saliva) was measured using Folin phenol reagent
as described by Lowry [24] and having bovine serum albumin as protein standard. Sample
absorbances were measured at 660 nm in a Beckman DU-800 spectrophotometer (Beckman,
Fullerton, CA).
Amylase activity (mg of maltose/mg of salivary protein) was determined by the method
described by Fisher and Stein [25] using a solution of maltose as standard. The color intensity
was measured at 530 nm on a Beckman DU-800 spectrophotometer (Beckman, Fullerton, CA).
Peroxidase activity was determined using Chandra’s method [26], as modified by Anderson
[27]. Interference due to pseudoperoxidase activity was eliminated by performing duplicate
assays in the presence of 10 mM 3-amino-1, 2 triazole, which is an inhibitor of peroxidase
activity. The absorbance was measured at 460 nm in a Beckman DU-800 spectrophotometer
(Beckman, Fullerton, CA). Concentrations of peroxidase in the samples are expressed in μg of
peroxidase/mg of protein, and these values were based on a standard curve constructed with
different concentrations of lactoperoxidase.
The Urea CE Kit (Labtest, Brazil) was used to determine blood urea nitrogen (BUN) and
urea concentrations in saliva. The developed color intensity was measured at 600 nm in a DU-
800 spectrophotometer (Beckman, Fullerton, CA), and a standard containing 70 mg/dL was
used to calculate the concentrations of the samples. The results are expressed as mg urea/dL of
blood or saliva.
Serum creatinine concentration was measured using a Labtest kit (Labtest). Samples were
analyzed at 520 nm in a DU-800 spectrophotometer (Beckman, Fullerton, CA). A standard
containing 4 mg/dL was used to calculate the unknown concentrations. The results are
expressed in mg creatinine/dL of blood or saliva.
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All results were statistically analyzed with analysis of variance (ANOVA) and Tukey's con-
trast tests, with an assumed level of significance of 5%. Pearson correlation analyses between
BUN and salivary urea results were also conducted using Minitab 16 software.
Results
No significant differences were observed in the initial and final body weights of the 3 experi-
mental groups at 8 or 12 weeks. Weekly water consumption was 50% higher in the CKD group
after 8 weeks (p<0.05) and remained over 50% higher until 12 weeks (p<0.05) after surgery
(Table 1). However, food intake did not change during these time periods (data not shown).
The presence of chronic kidney disease is demonstrated in Table 2. Significant increases in
BUN concentrations were observed at 8 and 12 weeks in the CKD groups compared to Sham
(138% and 88%, respectively) and Control (130% and 93%, respectively) groups. Significant
increases in serum creatinine were also observed in CKD animals at 8 weeks compared with
Sham (82%) and Control (35%) groups and at 12 weeks compared with Sham (63%) and Con-
trol (50%) group.
The salivary flow rate, total protein concentration, amylase activity, peroxidase activity and
salivary urea results from the Control, Sham and CKD groups following stimulation with pilo-
carpine or isoproterenol are presented in Tables 3 and 4, respectively.
The flow rate was not affected with pilocarpine stimulation at 8 or 12 weeks (Table 3). How-
ever, isoproterenol stimulation elicited significant decreases at 12 weeks (49%) compared with
the Sham group (Fig 1A).
Changes in total protein concentrations were observed only 12 weeks after surgery, with a
significant increase in response to pilocarpine stimulation (107%; Fig 2A), and a significant
decrease (29%) in response to isoproterenol stimulation, compared with the control animals.
The enzymatic activities of amylase and peroxidase were affected in the CKD groups. At 8
weeks, amylase activity was reduced in the CKD group in response to the isoproterenol stimu-
lus compared with the Sham (27%) and Control (44%) animals (Fig 1C). Pilocarpine stimulus
elicited a reduction in amylase activity of 45% compared with the Sham animals (Fig 2B). How-
ever, at 12 weeks, amylase activity was significantly increased in the CKD group in response to
isoproterenol stimulus compared with the Sham (140%) and Control (86%) groups (Fig 1B).
Significant reductions in peroxidase activity were observed in the saliva samples collected
after isoproterenol stimulation 8 weeks after surgery (approximately 50% compared with the
Sham and Control animals) and 12 weeks after surgery (approximately 40% compared with
the Sham and Control animals; Fig 1C). The pilocarpine stimulus elicited a large increase in
peroxidase activity in the CKD group 12 weeks after surgery (approximately 900% compared
with the Sham and Control animals; Fig 2C).
Salivary urea concentrations were significantly increased in the CKD groups at 8 and 12
weeks in response to the pilocarpine (over 100%) (Fig 2D) and isoproterenol (over 200%) sti-
muli compared with the Control and Sham groups (Fig 1D).
Fig 3 demonstrates the correlation between BUN and salivary urea concentrations including
all groups, salivary agonists, and experimental times (Pearson’s correlation R = 0.779, R2 =
0.607, p<0.01).
Discussion
Saliva is an important fluid in the oral cavity. The salivary composition is closely related to its
functions, which are important for the maintenance of oral health [28]. The salivary composi-
tion and flow rate are dependent on several factors, such as circadian rhythms, light exposure,
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degree of hydration, stimulus type, age and sex [29–31], and on the presence of systemic disor-
ders like chronic kidney disease.
To our knowledge, this is the first work that sought to determine the effects of 5/6 nephrec-
tomy, an experimental model for the study of CKD, on such a plethora of salivary parameters.
The difficulty to collect sufficient volume of in rest non-invasive saliva in rats restricts the
extrapolation of the present findings to a human non-pharmacologically manipulated clinical
condition, although clearly shows the pattern of secretion and salivary composition in response
to parasympathetic and sympathetic stimuli in rats with CKD.
The chosen model was the 5/6 nephrectomy, which causes renal function deficiencies due
to the long-term structural and functional adaptations of the remaining kidney tissue. How-
ever, during the experiment, renal function declined, causing systemic complications, such as
uremia [21, 32]. Some authors have described the experimental period of 8 weeks as a moderate
stage of CKD (reductions in renal function of approximately 50%) [19]. The experimental
period of 12 weeks was chosen to study the same parameters following a longer exposure.
The animals of this study were feed ad libitum with a standard chow, with casein as the pro-
tein source. One of the recommendations for controlling the progression of CKD is restricting
the dietary protein consumption [33]. A reduction or manipulation of the quality of the protein
source intake (e.g. soy) could influence the salivary changes with a slower or faster progression
of CKD, and changes in overall diet composition can also promote changes in salivary compo-
sition [34, 35].
Rats are widely used as experimental animals in studies of salivary secretion and salivary
gland morphology in several disorders. This animal was chosen due to the similarity of its sali-
vary glands to those of humans, particularly regarding the structural organization and the
secretion products [36]. Studies monitoring the salivary pharmacokinetic changes induced by
drugs, such as procainamide and ofloxacin, in rats with chronic renal impairment have been
Table 1. Weekly consumption of water from Control, Sham, and chronic kidney disease (CKD) groupsmeasured at 2, 4, 8 and 12 weeks of
experiment.
Groups Weeks
2 4 8 12
Control 237 ± 23 (n = 16) 210 ± 17 (n = 16) 223 ± 18 (n = 16) 214 ± 19 (n = 8)
Sham 208 ± 14 (n = 16) 200 ± 12 (n = 16) 233 ± 19 (n = 16) 219 ± 25 (n = 8)
CKD 277 ± 46* # (n = 16) 313 ± 51* # (n = 16) 388 ± 38* # (n = 16) 358 ± 93* # (n = 8)
Data (mean ± SD) expressed in milliliters. n = number of animals.
The * indicates differences from Control and # differences from Sham group (p<0.05), on the same experimental period.
doi:10.1371/journal.pone.0148742.t001
Table 2. BUN and creatinine concentrations of the Control, Sham and chronic kidney disease (CKD) groups at 8 and 12 weeks of experiment.
8 weeks 12 weeks
Control Sham CKD Control Sham CKD
BUN (mg/dL) 30.5 ± 3.78
(n = 19)
29.73 ± 2.06
(n = 16)
70.1 ± 14.76 * #
(n = 15)
30.85 ± 3.75
(n = 19)
32.1 ± 4.34
(n = 19)
60.07 ± 17.2 * #
(n = 17)
Creatinine (mg/
dL)
1.01 ± 0.4
(n = 19)
0.75 ± 0.12
(n = 16)
1.37 ± 0.35 * #
(n = 15)
0.74 ± 0.23
(n = 19)
0.68 ± 0.13
(n = 19)
1.11 ± 0.29 * #
(n = 17)
Values are expressed in mean ± SD. n = number of animals.
The * indicates differences from Control and # differences from Sham group (p<0.05), on the same experimental period.
doi:10.1371/journal.pone.0148742.t002
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reported [37, 38], but there are no studies that have used nephrectomy models to analyze the
salivary composition parameters and their correlations with serum changes resulting from the
disease.
In experimental models, salivary secretion can be stimulated by drugs. Pilocarpine has been
used as a parasympathetic agonist whilst isoproterenol has been used as a sympathetic agonist.
Sympathetic stimulation acts on the β-adrenergic receptors in salivary glands, resulting in
increased intracellular cAMP concentrations that activate protein kinase A (PKA), which
results in the production of saliva with a higher protein content and lower water volume. In
turn, parasympathetic stimulation acts on muscarinic cholinergic receptors to primarily acti-
vate phospholipase C, which subsequently causes an increase in the intracellular concentration
of calcium that leads to the secretion of great amounts of water and electrolytes. Under para-
sympathetic stimuli, saliva secretion is induced in response to the activation of protein kinase
C (PKC) and complex formation of Ca2+-calmodulin, a mechanism less efficient in protein
Table 3. Analysis of saliva stimulated by Pilocarpine (1mg/Kg of b.w.) of Control, Sham and chronic kidney disease (CKD) groups at 8 and 12
weeks of experiment.
8 weeks 12 weeks
Control Sham CKD Control Sham CKD
Flow rate (μL/min) 47.8 ± 11.4
(n = 9)
54.4 ± 15.5
(n = 8)
59.3 ± 14.8 (n = 9) 39.0 ± 10.6
(n = 10)
33.0 ± 9.5 (n = 9) 34.7 ± 13.0 (n = 8)
Protein (mg/ml) 0.98 ± 0.19
(n = 8)
0.90 ± 0.24
(n = 8)
1.04 ± 0.27 (n = 8) 1.25 ± 0.32
(n = 10)
1.42 ± 0.53
(n = 9)
2.56 ± 2.13 *
(n = 8)
Amylase (mg of maltose/mg
protein)
331 ± 80 (n = 9) 436 ± 100
(n = 7)
240 ± 142 # (n = 7) 273 ± 84 (n = 10) 234 ± 68 (n = 9) 211 ± 133 (n = 8)
Peroxidase (μg/mg protein) 1.47 ± 0.54
(n = 8)
1.41 ± 0.66
(n = 8)
1.50 ± 0.80 (n = 7) 5.14 ± 3.14
(n = 10)
5.96 ± 3.23
(n = 9)
46.4 ± 34.9 * #
(n = 8)
Salivary urea (mg/dL) 51.47 ± 7.5
(n = 8)
51.47 ± 6.2
(n = 8)
105.1±25.67 * #
(n = 8)
42.86 ± 4.9
(n = 7)
45.98 ± 6.51
(n = 7)
93.49 ± 20.7 * #
(n = 8)
Values are expressed in mean ± SD. n = number of animals.
The * indicates differences from Control and # differences from Sham group (p<0.05), on the same experimental period.
doi:10.1371/journal.pone.0148742.t003
Table 4. Analysis of saliva stimulated by Isoproterenol (5mg/Kg of b.w.) of Control, Sham and chronic kidney disease (CKD) groups at 8 and 12
weeks of experiment.
8 weeks 12 weeks
Control Sham CKD Control Sham CKD
Flow rate (μL/min) 7.52 ± 2.93
(n = 10)
7.65 ± 2.05
(n = 8)
6.04 ± 2.32 (n = 8) 10 ± 3.9 (n = 9) 13 ± 4.22 (n = 10) 6.68 ± 3.58 #
(n = 9)
Protein (mg/ml) 32.8 ± 2.5
(n = 10)
34.62 ± 2.13
(n = 8)
39.71 ± 7.29 (n = 8) 51.63 ± 4.8
(n = 7)
41.04 ± 6.94
(n = 10)
42.24 ± 4.55 *
(n = 7)
Amylase (mg of maltose/
mg protein)
5.37 ± 2.25
(n = 10)
4.12 ± 1.25
(n = 8)
3.03 ± 0.76 * #
(n = 8)
3.84 ± 0.76
(n = 7)
2.97 ± 0.56
(n = 10)
7.15 ± 5.8 * #
(n = 7)
Peroxidase (μg/mg
protein)
26.29 ±6.16
(n = 10)
27.32 ± 6.15
(n = 8)
12.62 ± 3.02 * #
(n = 8)
19.26 ± 3.0
(n = 7)
18.47 ± 6.7
(n = 10)
11.36 ± 1.5 * #
(n = 7)
Salivary urea (mg/dL) 49.74 ± 9.84
(n = 10)
42.84 ± 5.02
(n = 8)
147.96 ± 23.92 * #
(n = 8)
50.7 ± 7.45
(n = 7)
57.62 ± 9.1
(n = 10)
174.5± 93 * #
(n = 7)
Values are expressed in mean ± SD. n = number of animals.
The * indicates differences from Control and # differences from Sham group (p<0.05), on the same experimental period.
doi:10.1371/journal.pone.0148742.t004
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secretion than the one responsible for saliva secretion under sympathetic stimulation, thus
resulting in the production of fluid saliva with lower protein content and higher amount of
water and electrolytes [28, 39].
There is no consensus about the chronic kidney disease effects in the salivary flow. Several
authors have previously demonstrated that there are no changes in salivary flow in different
stages of the disease [12, 40], on the other hand, other studies found significant decreases, espe-
cially in patients undergoing hemodialysis, related to direct glandular damage and/or restric-
tion in fluid intake [17, 41]. In this study, the 12 weeks CKD animals exhibited significant
decreases of salivary flow comparing with Sham group under isoproterenol stimulus. Some
authors reported autonomic nervous system dysfunction in patients in pre-dialysis and dialysis
and also a hyperactivity of the sympathetic nervous system in uremia with decreased respon-
siveness of α- and β-adrenergic receptors, due to the chronic increase in sympathetic stimula-
tion [42, 43]. Thus, the lower responsiveness of glandular receptors could be responsible for
such decrease in salivary flow, but further studies are needed to confirm this hypothesis.
Fig 1. Representative graphics of analyzed saliva stimulated by isoproterenol (5mg/Kg of b.w.). (A) Salivary flow rate from Control, Sham and CKD
groups at the experimental period of 12 weeks. (B) Salivary amylase activities from Control, Sham and CKD groups at the experimental periods of 8 and 12
weeks. (C) Salivary peroxidase activities from Control, Sham and CKD groups at the experimental periods of 8 and 12 weeks. (D) Salivary urea
concentrations from Control, Sham and CKD groups at the experimental periods of 8 and 12 weeks. * indicates significant differences between indicated
groups (p< 0.05).
doi:10.1371/journal.pone.0148742.g001
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Amylase accounts for approximately 50% of the total protein produced by the salivary
glands [44–46]. It is a metalloenzyme that catalyzes the hydrolysis of glycosidic linkages in
polysaccharides, such as starch. Amylase is also important for the formation of the acquired
enamel pellicle and bacteria adhesion to the tooth surface. A significant increase in salivary
amylase activity was observed in CKD group in response to isoproterenol stimulation 12 weeks
after surgery. Hyperamylasemia is a common finding in patients with chronic renal failure.
Some authors have reported increases in serum, pancreatic and salivary amylase concentra-
tions in patients with varying degrees of chronic kidney disease and patients on hemodialysis
[12, 47]. However, the clinical significance of these findings remains unknown. Several authors
have unsuccessfully attempted to use the amylase activity level as a marker of pancreatic dam-
age in CKD. Although there is a consensus regarding the presence of hyperamylasemia in
CKD, it has not yet been possible to establish a numerical correlation between amylase activity
and disease stage. The observed high amylase concentration in saliva of animals with CKD con-
firms the previously observed clinical findings in patients.
Fig 2. Representative graphics of analyzed saliva stimulated by pilocarpine (1mg/Kg of b.w.). (A) Salivary total protein concentrations from Control,
Sham and CKD groups at the experimental period of 12 weeks. (B) Salivary amylase activities from Control, Sham and CKD groups at the experimental
periods of 8 weeks. (C) Salivary peroxidase activities from Control, Sham and CKD groups at the experimental period of 12 weeks. (D) Salivary urea
concentrations from Control, Sham and CKD groups at the experimental periods of 8 and 12 weeks. * indicates significant differences between indicated
groups (p< 0.05).
doi:10.1371/journal.pone.0148742.g002
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Peroxidase is an enzyme with antimicrobial properties that catalyzes the oxidation of thio-
cyanate (SCN-) in the presence of hydrogen peroxide (H2O2) to generate hypothiocyanate
(OSCN-), which inhibits bacterial growth, prevents the accumulation of this toxic substance,
and acts as an antioxidant enzyme [48]. At 8 weeks, decreased renal function led to a significant
decrease in peroxidase activity after isoproterenol stimulation. At 12 weeks, significant changes
in the activity of this enzyme were observed in the CKD group. Previous studies reported oxi-
dative stress in uremia, increased production of reactive oxygen species and decreased antioxi-
dant system activity in patients with chronic renal failure [49, 50]. Oxidative stress is a
potential mediator of cardiovascular, neurological, and inflammatory diseases related to
chronic renal failure [51]. The increase in peroxidase activity suggests that the changes in the
antioxidant systems of the salivary glands in the CKD group were the result of increased pro-
duction of free radicals in the disease.
Increases in serum creatinine and BUN concentrations are used to evaluate the presence
and severity of chronic kidney disease [20, 50]. In our study, after 8 weeks, these parameters
increased in the CKD group, and these increases remained constant after 12 weeks of the
experiment, relative to the control and sham groups; these findings are indicative of increased
retention of these compounds in response to reductions in the renal function in these animals.
The observed improvement in renal function at 12 weeks comparing with 8 weeks CKD ani-
mals can be related with the rats’ malnourishment as a consequence of the renal failure itself,
with underproduction of creatinine, in the absence of a better method to estimate the glomeru-
lar filtration rate. An increase in water consumption was also observed in the CKD group, but
no difference was seen in terms of food consumption. Polydipsia and polyuria are symptoms of
CKD and result from the body’s attempts to eliminate excess accumulations of toxic
substances.
The increased salivary urea concentration observed in the CKD animals was strongly and
positively correlated with the plasma concentration, which confirms the findings of clinical
studies that have demonstrated the potential of using saliva to identify markers of the disease.
Fig 3. Correlation between BUN and salivary urea concentrations. n = 105. Data were expressed in mg/
dL.
doi:10.1371/journal.pone.0148742.g003
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The use of saliva as a diagnostic tool has been highly recommended because saliva collection is
less invasive than blood collection and consequently more readily accepted by patients [52, 53].
In this study, we analyzed the effects of 5/6 nephrectomy on the composition of stimulated
saliva collected from rats with the intention of using this experimental animal model in future
studies of salivary gland dysfunction. The alterations observed in the saliva are very similar to
those that have been detected in patients, clearly demonstrating the viability of the 5/6 nephrec-
tomy animal model as an excellent experimental model for future studies that seek to under-
stand whether changes in salivary composition and salivary glands are promoted by CKD.
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